Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor
Vincent Mascitti(Pfizer (United States)), Yue Chen(Cedars-Sinai Medical Center), Kathleen A. Farley(Pfizer (United States)), Bruce A. Lefker(Pfizer (United States)), Ralph P. Robinson(Pfizer (United States)), Benjamin D. Stevens(Pfizer (United States)), Chulho Choi, Kentaro Futatsugi(Pfizer (United States)), Raman Sharma(Liverpool School of Tropical Medicine), Sophie Y. Lavergne(Pfizer (United States)), Peter Cornelius(East Carolina University), Michael J. Munchhof(Pfizer (United States)), Amit S. Kalgutkar(Pfizer (United States)), Kim F. McClure(Pfizer (United States)), Paul D. Bonin(Pfizer (United States)), Cristiano R. W. Guimarães(Pfizer (United States))
Cited by 29
Related Papers
Substrate and Functional Diversity of Lysine Acetylation Revealed by a Proteomics Survey
|Molecular Cell|2006|1.5k
Acetylation Is Indispensable for p53 Activation
|Cell|2008|828
Association between C-reactive protein-albumin-lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: From the investigation on nutrition status and clinical outcome of common cancers study
|Frontiers in Immunology|2023|204
Molecular Characterization of Propionyllysines in Non-histone Proteins
|Molecular & Cellular Proteomics|2008|167
In vitro and in vivo antioxidant effects of the ethanolic extract of Swertia chirayita
|Journal of Ethnopharmacology|2011|141